Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $92.29

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) have been given a consensus rating of “Moderate Buy” by the fourteen analysts that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, nine have issued a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $95.75.

Several research analysts have weighed in on the stock. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday. Morgan Stanley upped their price objective on PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a report on Friday. TD Cowen raised PTC Therapeutics from a “hold” rating to a “buy” rating and lifted their target price for the stock from $75.00 to $90.00 in a report on Friday, May 8th. Citigroup upgraded shares of PTC Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $75.00 to $108.00 in a research note on Tuesday, June 9th. Finally, Cantor Fitzgerald lifted their price objective on shares of PTC Therapeutics from $124.00 to $130.00 and gave the stock an “overweight” rating in a research note on Thursday, July 16th.

Insider Buying and Selling

In related news, CEO Matthew B. Klein sold 12,572 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $72.95, for a total value of $917,127.40. Following the completion of the transaction, the chief executive officer owned 393,998 shares in the company, valued at $28,742,154.10. This trade represents a 3.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mary L. Smith sold 15,834 shares of PTC Therapeutics stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $90.00, for a total transaction of $1,425,060.00. Following the sale, the director owned 21,813 shares in the company, valued at approximately $1,963,170. This represents a 42.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 198,662 shares of company stock valued at $16,347,994 in the last ninety days. Insiders own 5.50% of the company’s stock.

Institutional Trading of PTC Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of PTCT. UMB Bank n.a. acquired a new position in shares of PTC Therapeutics in the fourth quarter worth approximately $26,000. Comerica Bank raised its holdings in PTC Therapeutics by 868.5% during the 3rd quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 469 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in shares of PTC Therapeutics in the 4th quarter worth approximately $41,000. Allworth Financial LP boosted its stake in shares of PTC Therapeutics by 63.8% in the 4th quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 247 shares during the last quarter. Finally, First Horizon Corp bought a new stake in shares of PTC Therapeutics in the 4th quarter valued at $53,000.

PTC Therapeutics Price Performance

Shares of PTC Therapeutics stock opened at $68.01 on Monday. The business has a fifty day simple moving average of $77.57 and a two-hundred day simple moving average of $72.74. PTC Therapeutics has a 1 year low of $43.17 and a 1 year high of $90.87. The company has a market capitalization of $5.64 billion, a price-to-earnings ratio of -117.26, a P/E/G ratio of 6.58 and a beta of 0.53.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.24 by $0.68. The firm had revenue of $360.52 million for the quarter, compared to the consensus estimate of $298.63 million. PTC Therapeutics had a negative net margin of 3.80% and a negative return on equity of 362.45%. The company’s quarterly revenue was up 101.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.83) earnings per share. As a group, equities analysts anticipate that PTC Therapeutics will post 0.41 earnings per share for the current fiscal year.

PTC Therapeutics News Roundup

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
• Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.